



Commitment to Access to Medicines Policy

OUR COMMITMENT TO ACCESS TO MEDICINES

Arena Pharmaceuticals, Inc. and its subsidiaries (“Arena” or the “Company”) believes patients need better access to quality and affordable medicines. In connection with this stance, Arena strives to improve health outcomes globally with goals of delivering important and affordable medicines to those in need.

The Company employs the following strategies to address access-related issues:

Reducing Patient Burden: Arena fully supports programs that aim to reduce the burden patients face in gaining better access to clinical trials. Through its partnership with a large ridesharing company, Arena improves patient access to its investigational medicines by offering certain clinical trial participants transportation to and from trial sites. This gives patients a broadened range of access to care that could otherwise be unavailable to them due to geographical or economic barriers.

Supporting Patient Advocacy: Arena strongly supports patient advocacy initiatives. In early 2020, Arena Pharmaceuticals announced the launch of the Arena of Care Award in IBD, a competitive global grant opportunity to fund novel innovative programs that address significant unmet needs within the IBD community. The Company has committed to offering Arena of Care Awards in support of patient advocacy and patient-centric solutions for the next several years.

Expanded Clinical Trial Access: Arena recognizes that patients occasionally need expanded access to investigational compounds. With this practice in mind, the [Expanded Access Policy](#) was created to outline the formal procedures for submitting requests for access to investigational medicines in specific circumstances.